215656-99-8

Usage

Chemical Properties

Brown Solid

Uses

Intermediate in the production of antithrombotic agents.

Upstream product

• 610-81-1 4-hydroxy-2-nitroaniline 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 219518-89-5 N-(3-cyanobenzoyl)-2-nitro-4-(tert-butyldimethylsilyloxy)aniline 
• 219518-90-8 N₁-(3-cyanobenzoyl)-4-(dimethyl-t-butylsiloxy)-1,2-benzenediamine 
• 219518-92-0 N¹-(3-cyanobenzoyl)-N²-(4-isopropylbenzoyl)-4-hydroxy-1,2-benzenediamine 
• 219518-93-1 N¹-(3-(amino(hydroxyimino)methyl)benzoyl)-N²-(4-iso-propylbenzoyl)-4-hydroxy-1,2-benzenediamine 
• 219518-91-9 N¹-(3-cyanobenzoyl)-N²-(4-isopropylbenzoyl)-4-(tert-butyldimethylsilyloxy)-1,2-benzenediamine 
• 219518-98-6 N¹-(3-cyanobenzoyl)-N²-(4-iso-propylbenzoyl)-4-ethoxycarbonylmethoxy-1,2-benzenediamine 
• 219518-99-7 N¹-(3-(amino(hydroxyimino)methyl)benzoyl)-N²-(4-iso-propylbenzoyl)-4-ethoxycarbonylmethoxy-1,2-benzenediamine 
• 219518-95-3 N¹-(3-cyanobenzoyl)-N²-(4-isopropylbenzoyl)-4-benzyloxycarbonylmethoxy-1,2-benzenediamine 
• 219518-96-4 N¹-(3-(amino(hydroxyimino)methyl)benzoyl)-N²-(4-isopropylbenzoyl)-4-benzyloxycarbonylmethoxy-1,2-benzenediamine 
• 219519-20-7 N-(t-butoxycarbonyl)-2-nitro-4-(dimethyl-t-butylsiloxy)aniline 
• 201811-20-3 tert-butyl N-(4-hydroxy-2-nitrophenyl)carbamate 
• 726206-94-6 C₁₄H₂₀N₂O₅ 
• 726207-19-8 C₂₄H₂₀ClN₃O₆S 
• 1345687-91-3 4-{ [tert-butyl(dimethyl)silyl]oxy}-N¹-{4-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy]phenyl}benzene-1,2-diamine 

Relevant academic research and scientific papers

Synthesis and bioluminescence of electronically modified and rotationally restricted colour-shifting infraluciferin analogues

Synthetic nIR emitting luciferins can enable clearer bioluminescent imaging in blood and tissue. A limiting factor for all synthetic luciferins is their reduced light output with respect to D-luciferin. In this work we explore a design feature of whether

FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

Condensed tricyclic compounds as RAF kinase inhibitors

The invention provides certain condensed tricyclic compounds as well as salt, compositions and application methods thereof.

CONDENSED TRICYCLIC COMPOUNDS AS Raf KINASE INHIBITORS

PROBLEM TO BE SOLVED: To provide specific tricyclic compounds that can be useful for inhibiting Raf kinase and for treating disorders mediated by Raf kinase. SOLUTION: A compound is represented by the general formula 1 in the figure. (Q is C or N; W is C or N; X is CH2 or O; Y is NR12, O or S; Z is O, S, NR13, CO, SO, SO2 or CR13R14; R1 to R6 are each independently hydrogen, halogen, haloalkyl, alkyl or the like.) SELECTED DRAWING: None COPYRIGHT: (C)2017,JPO&INPIT

Membrane-permeable Mn(III) complexes for molecular magnetic resonance imaging of intracellular targets

Intracellular compartments make up roughly two-thirds of the body, but delivery of molecular imaging probes to these spaces can be challenging. This situation is particularly true for probes designed for detection by magnetic resonance imaging (MRI), a hi

FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

RADIOACTIVE FLUORINE-LABELED QUINOXALINE COMPOUND

Provided is a compound effective as a diagnostic imaging probe targeting amyloid and an agent for Alzheimer's disease diagnosis including the compound.

[5,6]HETEROCYCLIC COMPOUND

Abstract: An object of the present invention is to provide a novel low molecular weight compound exhibiting an osteogenesis-promoting action. This object is achieved by a compound having the general formula (I) or a pharmacologically acceptable salt thereof. In the general formula (I), R1 and R2 represent hydrogen atoms, and the like; R3 represents a hydrogen atom, and the like; X, Y, and Z represent nitrogen atoms, and the like; A represents a phenylene group, and the like; n represents 1 or 2, and the like; and V and W represent oxygen atoms, and the like.

FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

Structure-activity relationships and in vivo evaluation of quinoxaline derivatives for PET imaging of β-amyloid plaques

This letter describes the synthesis, structure-activity relationships, and in vivo evaluation of a new series of 2-phenylquinoxaline (PQ) derivatives for imaging β-amyloid (Aβ) plaques in Alzheimer's disease (AD). In experiments in vitro, the affinity of